ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elifibranor

Also written as “Elafibranor”, “GFT505 80mg” and “elafibranor”.

Its studies are mostly in Liver Cirrhosis, Biliary · Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.

Drug pageElifibranor: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 16, 201624 company-led studies, 5 open or runningNext primary completion: Dec 17, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genfit160 open or runningphase 3since Feb 16, 2016Dec 13, 2010none ahead
Ipsenits history only85 open or runningphase 3since Aug 21, 2020Aug 21, 2020Dec 17, 2026phase 3 · NCT06730061

Also a collaborator on its studies: Naturalpha, Premier Research Group, Eurofins Optimed and PhinC Development.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Genfit only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2010First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT01261494 · 97 enrolled · Bosnia and Herzegovina, Latvia, Macedonia, The Former Yugoslav Republic of and more
  2. Jan 4, 20113 phase 2 studiesNCT01271777, NCT01271751, NCT01275469
  3. Nov 15, 2011Phase 1 study in Diabetes Mellitus, Type 2NCT01474161 · 96 enrolled · France
  4. Sep 24, 2012Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT01694849 · 275 enrolled · United States, Belgium, France and more
  5. Mar 14, 2014Phase 1 study in Healthy VolunteersNCT02091310 · 200 enrolled · France
  6. May 16, 2014Phase 1 study in HealthyNCT02142127 · 6 enrolled · Belgium
  7. Feb 16, 2016Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT02704403 · 2,157 enrolled · United States, Argentina, Australia and more
  8. Mar 28, 2017Phase 2 study in Liver Cirrhosis, BiliaryNCT03124108 · 45 enrolled · United States, France, Germany and more
  9. Nov 30, 2018Phase 1 study in Liver DiseasesNCT03765671 · 30 enrolled · United States
  10. Feb 15, 2019Phase 1 study in Renal InsufficiencyNCT03844555 · 23 enrolled · France, Romania
  11. Mar 13, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03883607 · 10 enrolled · United States
  12. May 15, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03953456 · 17 enrolled · Netherlands
  13. Jun 11, 2019Phase 1 study in Drug-drug InteractionNCT03985969 · 26 enrolled · France
  14. Nov 19, 2019Phase 1 study in GeriatricsNCT04171752 · 21 enrolled · France

TargetBeta

PPARA →read by rule
“An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-alpha (PPARa) and -delta (PPARd), with bile acids reducing activity”NCIt, by rule

Other programs on PPARA

ProgramCompanyFurthest phaseStudies
saroglitazarruleZydus Lifesciencesphase 419
pemafibrateruleKowaphase 417
seladelparruleGilead Sciencesphase 314
chiglitazarruleChipscreen Biosciencesphase 39
Gemfibrozilrulepolaryx-therapeutics-incphase 38
lanifibranorinventiva-pharmaphase 36

Studies

All 16 Genfit leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04171752Geriatrics · France1CompletedMar 22, 202021
NCT03985969Drug-drug Interaction · France1CompletedMar 15, 202026
NCT03953456Non-alcoholic Fatty Liver Disease · Netherlands2TerminatedMar 11, 202017
NCT03883607Non-alcoholic Fatty Liver Disease · United States2TerminatedJun 16, 202010
NCT03844555Renal Insufficiency · France, Romania1CompletedMar 15, 202023
NCT03765671Liver Diseases · United States1CompletedJun 7, 201930
NCT03124108Liver Cirrhosis, Biliary · United States, France, Germany and more2CompletedOct 31, 201845
NCT02704403Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3TerminatedOct 28, 20202,157
NCT02142127Healthy · Belgium1CompletedJun 20146
NCT02091310Healthy Volunteers · France1CompletedDec 2014200
NCT01694849Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more2CompletedFeb 2015275
NCT01474161Diabetes Mellitus, Type 2 · France1CompletedNov 201296
NCT01275469Glucose Intolerance · France2CompletedDec 200947
NCT01271751Obesity, Abdominal · France, Romania, Tunisia2CompletedSep 200996
NCT01271777Insulin Resistance · France2CompletedNov 201122
NCT01261494Diabetes Mellitus, Type 2 · Bosnia and Herzegovina, Latvia, Macedonia, The Former Yugoslav Republic of and more2CompletedJun 201197

How it is read

Names in the registry

  • “Elafibranor”, 8 entries
  • “GFT505 80mg”, 5 entries
  • “elafibranor”, 4 entries
  • “Elafibranor 80mg”, 2 entries
  • “Elafibranor 80 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.